|
| 4-methyl-2-(4-methylphenyl)-6-{5-[(4-phenylpiperazin-1-yl)carbonyl]-1,2,4-oxadiazol-3-yl}-1,2,4-triazine-3,5(2H,4H)-dione |
|
Shigella |
TTSS (Type III secretion system) |
In vivo |
|
| 4-methyl-2-phenyl-6-{5-[(4-phenylpiperazin-1-yl)carbonyl]-1,2,4-oxadiazol-3-yl}-1,2,4-triazine-3,5(2H,4H)-dione |
|
Shigella |
TTSS (Type III secretion system) |
In vivo |
|
| 6-(4-((2,4-dimethylphenyl)sulfonyl)piperazin-1-yl)-N-(pyridin-4-yl)pyridazin-3-amine |
|
Shigella |
TTSS (Type III secretion system) |
In vivo |
|
| Cyto10C9 |
|
Brucella |
VirB type IV secretion system |
In vivo |
|
| 1-(2,4-dimethoxybenzyl)-4-(2,3-dimethylphenyl)piperazine |
|
Bacillus |
Nutritional/Metabolic factor |
In vitro |
|
| 3-cyclohexyl-1-[4-(2-methoxyphenyl)piperazin-1-yl]propan-1-one |
|
Clostridium |
TcdB (Toxin B) |
In vitro |
|
| Piperazinehexanamide derivative, 5 |
|
Coxiella
Legionella |
Dot/Icm T4SS
Dot/Icm (Defect in organella trafficking/intracellular multiplication) |
In vitro
In vitro |
|
| N-{1-[4-(4-FLUOROPHENYL)PIPERAZIN-1-YL]-1-(THIOPHEN-2-YL)PROPAN-2-YL}-N'-[(PYRIDIN-3-YL)METHYL]ETHANEDIAMIDE |
|
Mycobacterium |
Exoenzyme |
In vitro |
|
| N-[(FURAN-2-YL)METHYL]-N'-{1-[4-(4-METHOXYPHENYL)PIPERAZIN-1-YL]-1-(THIOPHEN-2-YL)PROPAN-2-YL}ETHANEDIAMIDE |
|
Mycobacterium |
Exoenzyme |
In vitro |
|
| furo[3,2-b]quinoxalin-3-yl-(4-phenylpiperazin-1-yl)methanone |
|
Pseudomonas |
TTSS (Type III secretion system) |
In vitro |
|
| | | |
